AstraZeneca wins a round in their PhIII COPD bout with GSK — but can they catch up?
AstraZeneca gets to build its case for their triple combo for COPD as regulators on both sides of the Atlantic give it a careful review. And that could trigger some added fretting at GSK, which has been looking to secure a beachhead on the COPD market with their own triple — Trelegy Ellipta.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 62,500+ biopharma pros reading Endpoints daily — and it's free.